Key Takeaways
- • Breakthrough Properties, a joint venture between Tishman Speyer and Bellco Capital, has raised $430 million at the first closing of its second life-science real estate fund, positioning it to deploy capital into distressed assets across US and European innovation clusters.
- • The fund targets a total capital commitment of $1.5 billion with subsequent closings planned for 2026, following the success of its inaugural fund which closed in 2022 with $3 billion in capital and assembled a portfolio of nearly 6 million square feet.
- • Breakthrough's portfolio includes marquee assets such as Torrey Heights in San Diego, One Helix in Amsterdam, and One Milestone at Harvard Enterprise Research Campus in Boston, demonstrating geographic and sectoral diversification across prime life-science real estate.
- • The first closing attracted institutional capital from global asset managers, investment advisers, pension funds, and family offices, reflecting institutional confidence in the life-sciences real estate thesis during a period of market dislocation.
- • CEO Dan Belldegrun characterized the current environment as "the most compelling investment window we've seen in years," citing transitory market dynamics, pricing disruption, reduced generalist investor participation, and constrained new supply as favorable conditions for value-add investment returns.
Summary
Breakthrough Properties, the life-science real estate joint venture between real estate developer Tishman Speyer and Bellco Capital, has secured $430 million in commitments at the first closing of its Growth Portfolio II fund. The capital raise represents a strategic re-entry into the market at a time when asset valuations have compressed and competition from generalist investors has diminished. The fund is targeting total capitalization of $1.5 billion, matching the size of Breakthrough's inaugural fund, with additional closings expected throughout 2026.
The first closing attracted a diversified institutional investor base comprising global asset managers, investment advisers, pension funds, and family offices. This composition reflects sustained institutional appetite for thematic real estate exposure despite broader market volatility. Breakthrough plans to deploy capital across a range of asset profiles—from core-plus to value-add opportunities—across leading US and European life-science innovation hubs, capitalizing on what it characterizes as favorable market conditions for acquisition at depressed valuations.
Breakthrough's track record provides institutional investors with demonstrated execution capability. The inaugural fund, which closed in 2022 with $3 billion in capital, assembled a portfolio spanning nearly 6 million square feet of institutional-quality life-science real estate. Key portfolio assets include Torrey Heights in San Diego, One Helix in Amsterdam, and One Milestone at the forthcoming Harvard Enterprise Research Campus in Boston. This geographic and functional diversification across the US and Europe mitigates concentration risk while capturing secular growth in biotech, pharmaceutical, and research infrastructure.
According to Dan Belldegrun, Breakthrough's CEO, the timing of the fund raise aligns with structural tailwinds in the life-sciences sector. He cited transitory market dislocations that have compressed pricing on high-quality assets, reduced competition from generalist investors retreating from the space, and constrained new supply as catalysts for an attractive vintage. Tishman Speyer's co-chairman Rob Speyer emphasized the strength of partnership relationships underpinning the raise, noting that the first closing "demonstrates the trust we've built with our investment partners."
The fund's focus on value-add returns across prime life-science real estate reflects confidence in the sector's long-term structural demand drivers, including continued biotech cluster consolidation, demand for specialized research infrastructure, and institutional capital's preference for thematic real estate exposure in high-growth sectors.
The first closing attracted a diversified institutional investor base comprising global asset managers, investment advisers, pension funds, and family offices. This composition reflects sustained institutional appetite for thematic real estate exposure despite broader market volatility. Breakthrough plans to deploy capital across a range of asset profiles—from core-plus to value-add opportunities—across leading US and European life-science innovation hubs, capitalizing on what it characterizes as favorable market conditions for acquisition at depressed valuations.
Breakthrough's track record provides institutional investors with demonstrated execution capability. The inaugural fund, which closed in 2022 with $3 billion in capital, assembled a portfolio spanning nearly 6 million square feet of institutional-quality life-science real estate. Key portfolio assets include Torrey Heights in San Diego, One Helix in Amsterdam, and One Milestone at the forthcoming Harvard Enterprise Research Campus in Boston. This geographic and functional diversification across the US and Europe mitigates concentration risk while capturing secular growth in biotech, pharmaceutical, and research infrastructure.
According to Dan Belldegrun, Breakthrough's CEO, the timing of the fund raise aligns with structural tailwinds in the life-sciences sector. He cited transitory market dislocations that have compressed pricing on high-quality assets, reduced competition from generalist investors retreating from the space, and constrained new supply as catalysts for an attractive vintage. Tishman Speyer's co-chairman Rob Speyer emphasized the strength of partnership relationships underpinning the raise, noting that the first closing "demonstrates the trust we've built with our investment partners."
The fund's focus on value-add returns across prime life-science real estate reflects confidence in the sector's long-term structural demand drivers, including continued biotech cluster consolidation, demand for specialized research infrastructure, and institutional capital's preference for thematic real estate exposure in high-growth sectors.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.